Trial Profile
A Multi-center, Uncontrolled, Open-label, Evaluation of Lamotrigine Monotherapy on Newly Diagnosed Typical Absence Seizures in Children and Adolescents.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Jul 2023
Price :
$35
*
At a glance
- Drugs Lamotrigine (Primary)
- Indications Absence epilepsy; Epilepsy
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 01 Oct 2018 Results published in the Brain and Development
- 13 Jan 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 15 Oct 2015 Planned End Date changed from 1 Sep 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov record.